sirukumab: Clinical Trials

16 trials of sirukumab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 2 withdrawn, 1 terminated. 7 Phase 3, 5 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 37Completed 5, Terminated 1, Withdrawn 1
Phase 25Completed 4, Withdrawn 1
Phase 14Completed 4

Follow sirukumab: new trials by email Literature Review of sirukumab trials Research Report on sirukumab

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19
Sirukumab, Placebo, Standard of Care (SOC) - Critical Confirmed Coronavirus Disease (COVID)-19
Phase 2CompletedJanssen Pharmaceutica N.V., Belgium2122020-04-242022-06-21
Efficacy and Safety Study of Sirukumab in Subjects With Polymyalgia Rheumatica
Sirukumab, Placebo to match sirukumab, Prednisone /Prednisone placebo - Polymyalgia Rheumatica
Phase 3WithdrawnGlaxoSmithKline2018-03-152017-11-20
A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma
Sirukumab, Placebo, Rescue medication - Asthma
Phase 2WithdrawnGlaxoSmithKline2016-09-232018-08-31
Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis
Sirukumab, Placebo to match sirukumab, Prednisone - Giant Cell Arteritis
Phase 3TerminatedGlaxoSmithKline1612015-10-162019-07-31
An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder
Sirukumab 50 mg, Placebo - Depressive Disorder, Major
Phase 2CompletedJanssen Research & Development, LLC1932015-07-232025-04-29
A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis
adalimumab 40 mg, sirukumab 100 mg, sirukumab 50 mg - Arthritis, Rheumatoid
Phase 3CompletedJanssen Research & Development, LLC5592014-04-042017-10-26
Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants
Sirukumab (IV infusion), Sirukumab (SC injection with PFS-U), Sirukumab (SC injection with PFS-AI) - Healthy
Phase 1CompletedJanssen Research & Development, LLC1442014-03-012016-03-09
Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003
Sirukumab 100 mg, Sirukumab 50 mg, Placebo - Arthritis, Rheumatoid
Phase 3CompletedJanssen Research & Development, LLC18202013-08-072019-05-06
A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine
Sirukumab 100 mg, Sirukumab 50 mg, Placebo - Arthritis, Rheumatoid
Phase 3CompletedJanssen Pharmaceutical K.K.1222012-11-012016-10-27
A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis
Sirukumab, Midazolam, Warfarin - Arthritis, Rheumatoid
Phase 1CompletedJanssen Research & Development, LLC122012-10-112017-03-07
A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)
Placebo, Sirukumab - Arthritis, Rheumatoid
Phase 3CompletedJanssen Research & Development, LLC16702012-08-152018-01-11
A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)
Placebo, Sirukumab - Arthritis, Rheumatoid
Phase 3CompletedJanssen Research & Development, LLC8782012-08-062018-03-23
An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis
CNTO 136, Placebo - Lupus Nephritis
Phase 2CompletedJanssen Research & Development, LLC252011-08-012016-03-24
A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers
CNTO 136 - Healthy
Phase 1CompletedCentocor, Inc.622009-01-012010-04-27
A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
CNTO 136 100 mg, CNTO 136 50 mg, CNTO 136 25 mg - Arthritis, Rheumatoid
Phase 2CompletedCentocor, Inc.1872008-08-112018-01-23
A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus
1 mg/kg CNTO 136, 4 mg/kg CNTO 136, 10 mg/kg CNTO 136 - Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic
Phase 1CompletedCentocor Research & Development, Inc.492007-03-012012-10-08

Conditions studied

Arthritis, Rheumatoid (7)  ·  Asthma (1)  ·  COVID-19 (1)  ·  Depressive Disorder, Major (1)  ·  Giant Cell Arteritis (1)  ·  Glomerulonephritis (1)  ·  Kidney Diseases (1)  ·  Lupus Erythematosus, Cutaneous (1)  ·  Lupus Erythematosus, Systemic (1)  ·  Lupus Nephritis (1)  ·  Polymyalgia Rheumatica (1)  ·  Proteinuria (1)

Sponsors

Janssen Research & Development, LLC (8)  ·  GlaxoSmithKline (3)  ·  Centocor, Inc. (2)  ·  Centocor Research & Development, Inc. (1)  ·  Janssen Pharmaceutica N.V., Belgium (1)  ·  Janssen Pharmaceutical K.K. (1)

Countries

United States (11)  ·  Poland (8)  ·  Mexico (6)  ·  Russia (6)  ·  Germany (5)  ·  Japan (5)  ·  South Korea (5)  ·  Spain (5)  ·  Belgium (4)  ·  Bulgaria (4)  ·  Canada (4)  ·  Lithuania (4)  ·  Netherlands (4)  ·  South Africa (4)  ·  United Kingdom (4)

Results publications

PMID 23896980, PMID 24699939, PMID 27110697, PMID 28215362, PMID 28855173, PMID 29483080, PMID 29514712, PMID 32844378, PMID 33526709, PMID 39362933

NIH funding

2014 (1)